tiprankstipranks
Evoke Pharma Strikes Deal to Offer Stocks and Warrants
Company Announcements

Evoke Pharma Strikes Deal to Offer Stocks and Warrants

Evoke Pharma (EVOK) has released an update to notify the public and investors about an entry into a material definitive agreement.

Don't Miss Our Christmas Offers:

Evoke Pharma, Inc. has partnered with underwriters to sell over 5 million common stock units at $0.68 each and nearly 6 million pre-funded warrant units at just under $0.68 each. These units include a mix of shares and warrants with varying expiration dates and exercise prices. The deal, which is aimed to net the company around $6.1 million after costs and is contingent on standard closing conditions, is scheduled to complete around February 13, 2024. This public offering is part of a pre-approved registration with the SEC, positioned to attract investors looking for diverse options in the pharma sector.

For further insights into EVOK stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TheFlyEvoke underscores committment to patients after FDA update on domperidone
TheFlyEvoke receives notice of allowance for two additional patent applications
TipRanks Auto-Generated NewsdeskEvoke Pharma Reports Q3 2024 Financial Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App